Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline.

The United Kingdom’s innovation agency is providing funding to set up an antibiotic drug discovery unit.

A phase 2 trial of Xenon Pharmaceuticals’ acne candidate XEN801 has missed its primary and key secondary efficacy endpoints.

During his budget blueprint announced earlier this month, President Donald Trump announced swingeing cutbacks across federal programs, with the National…

Fierce 15 winner C4 Therapeutics has become the latest biopharma to strike a deal with the Google-backed life sciences company Calico, although true to its…

Shares in Ultragenyx weakened after a midpipeline drug candidate missed its targets in a trial for a rare genetic disorder.

Former FDA commissioner Robert Califf, who was not asked back into his role by President Donald Trump, has become the new chair of the newly formed People-…

Akashi Therapeutics has been given the FDA go-ahead to restart tests for its Duchenne muscular dystrophy candidate HT-100 (delayed-release halofuginone), just…

Quiet upstart BioClin Therapeutics has raised $30 million in a Series B funding round, taking its total to $59 million since its founding, as it aims to push…

R&D